WALVAX and Zhiyu Biosciences reach strategic cooperation
June 19, 2025
Source: drugdu
52
On June 18, WALVAX announced that the company has established a strategic partnership with Shanghai Zhiyu Biotechnology Co., Ltd. ("Zhiyu Bio" for short). The core of this strategic cooperation between the two parties is to apply Zhiyu Bio's AI modeling combined with physical simulation biocomputing technology to WALVAX's human vaccine research and development field, focusing on using AI technology to accelerate the process development process such as protein (including enzyme) discovery and design, providing AI biocomputing platform licensing services to build intelligent R&D infrastructure, and providing deeply customized AI biocomputing solutions for the needs of specific vaccine products.
https://finance.eastmoney.com/a/202506183433263559.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
- LH-1801 project enters Phase III clinical trial July 7, 2025
- The new generation of DNA biosynthesis technology is moving towards industrialization July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
